Sustained Release Agent

Abstract Background: Modification of commercially available medicine, e.g. splitting or dissolving of tablets or pharmacy compounding, is current clinical practice when desired oral dosage forms are unavailable. These practices are defined as conventional pharmacy compounding techniques and are…
Read More...

BASF Pharma Solutions offers film-forming polymers and additive chemistries for your aesthetic, protective, and functional coating needs. BASF’s Kollicoat® portfolio provides easy-to-use coating options based on your tablet’s needs and desired functionality. Products from our Kolliphor®,…
Read More...

Abstract Over the past decades, a variety of controlled-release technologies have been developed to maintain a constant drug release rate in vivo. Osmotic pumps offer precise control and are widely used in marketed formulations. However, the manufacturing of osmotic pump tablets often involves…
Read More...

Abstract Inflammatory skin diseases are chronic conditions that significantly affect patients’ skin health and quality of life. Traditional treatments, including systemic immunosuppressants and topical therapies, often face limitations such as low efficacy, inadequate skin penetration, and severe…
Read More...

Abstract Imidafenacin tablets are the first-line drug for the treatment of overactive bladder (OAB). However, the tablets need to be taken twice daily for up to 3–6 months, which highly reduces patient compliance. This study aimed to develop a long-acting imidafenacin transdermal patch (LAITP) with…
Read More...

Abstract Aim: The study aimed to develop a once-daily sustained-release gastroretentive combination formulation of bepotastine besilate and montelukast sodium using multilayer tablet technology and gastro-retentive systems for the treatment of allergic rhinitis and asthma. Background:…
Read More...

Abstract Linezolid (LNZ), oxazolidinone antibiotic, is widely used in clinical practice for treatment of bacterial keratitis. Despite its efficacy, the application of LNZ in ophthalmic delivery is hindered by significant precorneal drug loss and poor ocular bioavailability. In this study,…
Read More...

Patients and caregivers experience challenges following a prescribed medicine routine. If the active pharmaceutical ingredients (API) are released quickly then patients may require multiple doses of the drug. That is to maintain treatment effectiveness. Uneven treatment and adverse effects can arise…
Read More...

Abstract Protein and peptide drugs (PPDs) are highly effective therapies for a wide range of diseases, including cancer, diabetes, and autoimmune disorders . However, delivering these drugs orally presents significant challenges. PPDs face substantial barriers to attaining oral bioavailability,…
Read More...

Abstract Poly(lactide-co-glycolide) (PLGA) implants have become a cornerstone in drug delivery and regenerative medicine due to their biocompatibility, tunable degradation, and capacity for sustained, localized therapeutic release. Recent innovations in polymer design, fabrication methods, and…
Read More...